Yvan Beaussant - Acceptability of psilocybin-assisted group therapy for cancer-related depression

Psilocybin-assisted group therapy is analyzed in a mixed-method clinical study as a sustainable treatment model for cancer-related depression. By incorporating group-based sessions alongside standardized therapy, this approach expands care capacity while addressing the unique existential and social challenges faced by terminal patients. Quantitative results demonstrate that participants experienced sustained depression relief, while qualitative interviews highlight the psychological benefits of shared experiences and community support. The findings suggest that grouping patients fosters deeper connection, safety, and self-transcendence, which significantly enhances the therapeutic outcomes of psychedelic-assisted care in oncology settings.